Assessment and clinical implications of cardioselectivity.
作者信息
Wale J L, Fitzgerald J D
出版信息
Proc R Soc Med. 1977;70(Suppl 5):45-7. doi: 10.1177/00359157770700S519.
Abstract
摘要
相似文献
1
Assessment and clinical implications of cardioselectivity.心脏选择性的评估及其临床意义
Proc R Soc Med. 1977;70(Suppl 5):45-7. doi: 10.1177/00359157770700S519.
2
The determination of beta-adrenoceptor antagonist cardioselectivity "in vivo": atenolol in anaesthetized cats.“体内”β-肾上腺素能受体拮抗剂心脏选择性的测定：麻醉猫体内的阿替洛尔
Arch Int Pharmacodyn Ther. 1983 Jul;264(1):59-72.
3
Cardioselectivity as a function of molecular structure in beta-adrenoceptor blocking agents of the 1-(para-substituted aryloxy)-3-(isopropylamino)propan-2-ol type.1-（对-取代芳氧基）-3-（异丙氨基）丙-2-醇类β-肾上腺素能阻滞剂中，心脏选择性与分子结构的关系。
J Med Chem. 1978 Sep;21(9):982-4. doi: 10.1021/jm00207a025.
4
Cardioselectivity of beta-adrenoceptor blocking agents 1. 1-[(4-Hydroxyphenethyl)amino]-3-(aryloxy)propan-2-ols.β-肾上腺素受体阻断剂的心脏选择性 1. 1-[(4-羟基苯乙基)氨基]-3-(芳氧基)丙-2-醇。
J Med Chem. 1979 Jun;22(6):735-7. doi: 10.1021/jm00192a022.
5
The assessment of the beta-adrenoceptor blocking activity and cardioselectivity of Koe 3290 in normal subjects.Koe 3290在正常受试者中的β-肾上腺素能受体阻断活性及心脏选择性评估。
Br J Clin Pharmacol. 1987 Nov;24(5):581-9. doi: 10.1111/j.1365-2125.1987.tb03216.x.
6
Haemodynamic consequences of intrinsic sympathomimetic activity and cardioselectivity in beta-blocker therapy for hypertension.β受体阻滞剂治疗高血压时内在拟交感活性和心脏选择性的血流动力学后果。
Eur Heart J. 1983 Jul;4 Suppl D:31-41. doi: 10.1093/eurheartj/4.suppl_d.31.
7
An investigation of "absolute plasma level effect relationships" and "absolute cardioselectivity" with respect to beta-adrenoceptor blockade.关于β-肾上腺素能受体阻断的“绝对血浆水平效应关系”和“绝对心脏选择性”的研究。
Eur J Clin Pharmacol. 1977 Aug 17;12(1):7-13. doi: 10.1007/BF00561399.
8
Ancillary pharmacologic properties of acebutolol: cardioselectivity, partial agonist activity, and membrane-stabilizing activity.醋丁洛尔的辅助药理学特性：心脏选择性、部分激动剂活性和膜稳定活性。
Am Heart J. 1985 May;109(5 Pt 2):1137-44. doi: 10.1016/0002-8703(85)90698-2.
9
Comparative evaluation of cardioselectivity of metoprolol OROS and atenolol: a double-blind, placebo-controlled crossover study.美托洛尔渗透泵控释片与阿替洛尔心脏选择性的比较评价：一项双盲、安慰剂对照的交叉研究。
Am Heart J. 1990 Aug;120(2):467-72. doi: 10.1016/0002-8703(90)90106-8.
10
Beta-adrenergic blockade of the lung. Dose-dependent cardioselectivity of tolamolol in asthma.肺的β-肾上腺素能阻断作用。托拉洛尔在哮喘中的剂量依赖性心脏选择性。
Chest. 1978 Jun;73(6):807-12. doi: 10.1378/chest.73.6.807.
引用本文的文献
1
Asthma and beta-blockers.哮喘与β受体阻滞剂
Eur J Clin Pharmacol. 1982;22(6):501-9. doi: 10.1007/BF00609622.
本文引用的文献
1
Human pharmacology: comparison of intravenous isoprenaline and salbutamol in asthmatic patients.人体药理学：哮喘患者静脉注射异丙肾上腺素与沙丁胺醇的比较。
Postgrad Med J. 1971 Mar;47:Suppl:38-9.
2
Beta adrenergic blockade in hypertension. Practical and theoretical implications of long-term hemodynamic variations.高血压中的β肾上腺素能阻滞剂。长期血流动力学变化的实际和理论意义。
Am J Cardiol. 1972 May;29(5):633-40. doi: 10.1016/0002-9149(72)90164-6.
3
Effect of a new beta-adrenergic blocking agent, ICI 66o82, on exercise haemodynamics and airway resistance in angina pectoris.新型β-肾上腺素能阻滞剂ICI 66082对心绞痛患者运动血流动力学和气道阻力的影响。
Br Heart J. 1974 Dec;36(12):1194-1200. doi: 10.1136/hrt.36.12.1194.
Zotero 插件